These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.
The acetaminophen and ibuprofen combination was approved for IV use, and as an adjunct to opioid therapy for the treatment of pain.
Exuua was approved for major depressive disorder, while two diabetes medications receive generic approvals.
A new combination of acetaminophen and ibuprofen will soon hit the market.
Tzield (teplizumab-mzwv) injections can delay onset by several months or years.
This antidepressant can yield results as soon as one week, which could generate popularity.
As opioid prescribing continues to decline, more nuanced and population-specific drug trends emerge as cost drivers.
A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.
